HK1057752A1 - N-phenyl-2-pyrimidine-amine derivatives - Google Patents

N-phenyl-2-pyrimidine-amine derivatives

Info

Publication number
HK1057752A1
HK1057752A1 HK03108645A HK03108645A HK1057752A1 HK 1057752 A1 HK1057752 A1 HK 1057752A1 HK 03108645 A HK03108645 A HK 03108645A HK 03108645 A HK03108645 A HK 03108645A HK 1057752 A1 HK1057752 A1 HK 1057752A1
Authority
HK
Hong Kong
Prior art keywords
pyrimidine
phenyl
amine derivatives
preparation
medicaments
Prior art date
Application number
HK03108645A
Other languages
English (en)
Inventor
Hans Michael Buerger
Giorgio Caravatti
Juerg Zimmermann
Paul William Manley
Werner Breitenstein
Margaret Amelia Cudd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1057752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1057752A1 publication Critical patent/HK1057752A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
HK03108645A 2000-09-13 2003-11-26 N-phenyl-2-pyrimidine-amine derivatives HK1057752A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0022438.6A GB0022438D0 (en) 2000-09-13 2000-09-13 Organic Compounds
PCT/EP2001/010503 WO2002022597A1 (en) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
HK1057752A1 true HK1057752A1 (en) 2004-04-16

Family

ID=9899367

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108645A HK1057752A1 (en) 2000-09-13 2003-11-26 N-phenyl-2-pyrimidine-amine derivatives

Country Status (14)

Country Link
US (3) US7081532B2 (xx)
EP (1) EP1322634B1 (xx)
JP (1) JP2004509111A (xx)
CN (2) CN1872850A (xx)
AT (1) ATE452129T1 (xx)
AU (1) AU2002218167A1 (xx)
BR (1) BR0113838A (xx)
CA (2) CA2416274C (xx)
DE (1) DE60140814D1 (xx)
ES (1) ES2336891T3 (xx)
GB (1) GB0022438D0 (xx)
HK (1) HK1057752A1 (xx)
PT (1) PT1322634E (xx)
WO (1) WO2002022597A1 (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
EP1408978A4 (en) * 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
ATE447560T1 (de) * 2002-06-28 2009-11-15 Nippon Shinyaku Co Ltd Amidderivat
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7629347B2 (en) * 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
AU2003242988A1 (en) * 2003-06-06 2005-01-04 Adibhatla Kali Sathya Bhujanga Rao Process for the preparation of the anti-cancer drug imatinib and its analogues
MXPA05013349A (es) * 2003-06-13 2006-03-09 Novartis Ag Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
CA2551529C (en) 2003-12-25 2011-02-01 Nippon Shinyaku Co., Ltd. Amide derivative and medicine
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
WO2006017353A2 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
WO2006136391A2 (en) * 2005-06-23 2006-12-28 Novartis Ag Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
US7514447B2 (en) * 2005-09-27 2009-04-07 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
EP2471529A3 (en) 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
KR20090061068A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 이매티닙의 제조 방법
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
MX2009011950A (es) * 2007-05-04 2009-12-11 Irm Llc Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
US20090012296A1 (en) * 2007-05-29 2009-01-08 Alexandr Jegorov Processes for the preparation of crystalline form beta of imatinib mesylate
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
ES2368876T3 (es) 2007-08-22 2011-11-23 Irm Llc Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
MX2010002004A (es) 2007-08-22 2010-03-11 Irm Llc Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
WO2009079797A1 (en) * 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
AU2009213153A1 (en) * 2008-02-11 2009-08-20 Institute Of Enzymology, Biological Research Center, Hungarian Academy Of Sciences Compounds with MDR1-inverse activity
LT2265607T (lt) * 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
JP2011526292A (ja) * 2008-06-27 2011-10-06 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 神経線維腫および関連する腫瘍を抑制および／または治療する物質および方法
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
US8178529B2 (en) 2009-04-15 2012-05-15 Astrazeneca Ab Imidazole substituted pyrimidines
US8530492B2 (en) * 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120388A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
CN102212057B (zh) * 2011-04-13 2013-11-27 合肥工业大学 一种羧酸类非甾体抗炎药衍生物及其制备方法和用途
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CN102796110B (zh) * 2011-05-23 2016-03-30 复旦大学 苯胺嘧啶化合物及其制备方法和用途
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103044394A (zh) * 2012-12-20 2013-04-17 北京理工大学 一种苯基氨基嘧啶衍生物及其制备方法和用途
CN103058935B (zh) * 2013-01-15 2015-05-06 四川大学 一种嘧啶类化合物及其制备方法和用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105859683B (zh) * 2016-04-11 2018-09-28 连云港恒运药业有限公司 伊马替尼的高纯度工业制备工艺
CN107805240A (zh) * 2016-09-08 2018-03-16 中国科学院合肥物质科学研究院 一种新型的pdgfr激酶抑制剂及其用途
CN107652266A (zh) * 2017-10-27 2018-02-02 上海应用技术大学 一种靶向酪氨酸激酶小分子抑制剂及其应用
EP3935057A4 (en) * 2019-03-05 2023-03-01 Hongyi & Associates LLC COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER
CN110078708B (zh) * 2019-05-08 2020-12-11 东南大学 Smo/Bcr-Abl双靶向抑制剂及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (xx) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
ES2336891T3 (es) 2010-04-19
BR0113838A (pt) 2003-06-03
ATE452129T1 (de) 2010-01-15
PT1322634E (pt) 2010-02-22
EP1322634B1 (en) 2009-12-16
WO2002022597A1 (en) 2002-03-21
EP1322634A1 (en) 2003-07-02
US7329661B2 (en) 2008-02-12
CA2416274C (en) 2011-01-04
US7081532B2 (en) 2006-07-25
US20070265292A1 (en) 2007-11-15
US7312216B2 (en) 2007-12-25
JP2004509111A (ja) 2004-03-25
DE60140814D1 (de) 2010-01-28
CA2687476A1 (en) 2002-03-21
GB0022438D0 (en) 2000-11-01
AU2002218167A1 (en) 2002-03-26
US20060223818A1 (en) 2006-10-05
CN1525967A (zh) 2004-09-01
CN1872850A (zh) 2006-12-06
US20040102453A1 (en) 2004-05-27
CA2416274A1 (en) 2002-03-21
CN100406452C (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MXPA04000577A (es) Derivados de dolastatina 10.
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
TW200510392A (en) Chemical compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
GB0112348D0 (en) Compounds
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
TW200505452A (en) Chemical compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BG106155A (en) Novel derivatives and analogues of galanthamin
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
TW200504051A (en) Novel acridine derivatives and their use as medicaments
AU2001266019A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140911